Beyond its primary GHS-R1a engagement, Hexarelin demonstrates binding activity at CD36 receptors a scavenger receptor expressed in cardiac tissue, macrophages, and endothelial cells a secondary mechanism that has generated substantial independent research interest in cardiovascular biology entirely separate from its growth hormone secretagogue function. This dual receptor profile is scientifically unique within the GHRP class and positions Hexarelin as a compound of relevance across both endocrinological and cardiovascular research disciplines simultaneously.

Its GHS-R1a-mediated growth hormone release is among the most robust documented within the secretagogue class, stimulating significant pituitary growth hormone output while also demonstrating activity on hypothalamic growth hormone regulation engaging both central and pituitary components of the growth hormone axis. Researchers investigating the comparative potency of growth hormone secretagogues frequently include Hexarelin as a high-potency reference compound.

Research applications include high-potency GHS-R1a receptor binding and activation studies, comparative GHRP class secretagogue potency investigations, growth hormone pulse amplitude and hypothalamic-pituitary axis research, CD36 receptor signaling and cardiovascular biology studies, cardiac tissue protection and function mechanism research, myocardial response to GHS-R1a independent CD36 engagement, and growth hormone downstream metabolic and anabolic signaling pathway investigations.

Every vial is independently third-party tested via HPLC and mass spectrometry, supplied with complete COA documentation confirming sequence accuracy and 99%+ purity. 

Molecular Formula: C₄₇H₅₈N₁₂O₆
Molecular Weight: 887.05 g/mol
Storage: Lyophilized at −20°C | Reconstitute under sterile conditions

FOR RESEARCH USE ONLY